Skysona Market Report 2026

Skysona Market Overview

• The Skysona market growth in the historic period has been driven by limited treatment options for CALD, advances in gene-editing technologies • Market expansion is supported by increasing approvals of gene therapies, rising investment in rare disease pipelines • Growth Driver: Rising Prevalence Of Rare Diseases Driving Market Growth • Market Trend: Regulatory Safety Enhancements in Gene Therapy • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Skysona Market?

Skysona refers to a gene therapy designed to slow the progression of cerebral adrenoleukodystrophy (CALD), a rare genetic disorder affecting the nervous system in young boys. The mechanism of action involves using a patient's own stem cells, which are modified to produce a functional version of the ABCD1 gene, responsible for producing an enzyme that helps break down fatty acids. The main indication of skysona include cerebral adrenoleukodystrophy (CALD). Cerebral adrenoleukodystrophy (CALD) refers to a rare, genetic neurodegenerative disorder that primarily affects boys and is characterized by the progressive loss of brain function due to the buildup of very long-chain fatty acids in the nervous system. The various formulations involve intravenous infusion. The several patient demographics include pediatric patients and adult patients and are distributed through multiple channels such as hospitals, specialty clinics, and online pharmacies. The various end-user includes academic and research institutes, biopharmaceutical companies, and patient advocacy groups.

What Is The Skysona Market Growth Forecast?

The growth in the forecast period can be attributed to increasing approvals of gene therapies, rising investment in rare disease pipelines, growing adoption of personalized medicine, expansion of advanced therapy manufacturing capacity, increasing long-term outcome monitoring frameworks. Major trends in the forecast period include increasing adoption of gene therapy for rare diseases, growing use of autologous stem cell modification, expansion of one-time curative treatment models, rising focus on pediatric genetic disorders, enhanced regulatory support for advanced therapies.

Global Skysona Market Segmentation

1) By Indication: Early-Stage Cerebral Adrenoleukodystrophy (CALD), Active Inflammatory CALD, Progressive CALD, Childhood-Onset CALD 2) By Formulation:Autologous CD34+ Hematopoietic Stem Cell Gene Therapy, Ex Vivo Lentiviral Vector–Modified Cell Therapy, Single-Administration Gene Therapy 3) By Patient Demographics: Pediatric Patients, Adult Patients 4) By Distribution Channel: Hospitals, Specialty Clinics, Online Pharmacies 5) By End-User: Academic And Research Institutes, Biopharmaceutical Companies, Patient Advocacy Groups

What Is The Driver Of The Skysona Market?

The increase in the prevalence of rare diseases is expected to propel the growth of the skysona market going forward. Rare diseases refer to medical conditions that affect a small proportion of the population. The increase in the prevalence of rare diseases is attributed to several factors, including improved diagnostic techniques, better awareness among healthcare professionals, and advancements in genetic testing. Skysona is useful for rare diseases, specifically cerebral adrenoleukodystrophy (CALD), as it offers a gene therapy approach that addresses the genetic mutation causing the disease, potentially improving neurological outcomes and extending survival in affected children. For instance, in August 2024, according to ALD Info, a Netherlands-based community-driven initiative that thrives on the sharing of information and collaboration among ALD experts across various fields, the incidence of adrenoleukodystrophy (ALD) is around 1 in 17,000 newborns. A male newborn has a 35-40% risk of developing cerebral ALD between ages 3 and 18, though it can also manifest in adulthood. Therefore, an increase in the prevalence of rare diseases drives the skysona industry.

Key Players In The Global Skysona Market

Major companies operating in the skysona market are Bluebird bio Inc.

Global Skysona Market Trends and Insights

Major companies operating in the Skysona market are focusing on technological advancements, such as regulatory driven safety label optimization, to gain a competitive advantage. This process involves updating clinical and safety information based on real-world evidence and regulatory feedback to refine patient eligibility and risk management. For instance, in August 2025, Bluebird Bio, a US based biotechnology company, introduced revised SKYSONA (elivaldogene autotemcel) labeling after FDA review. The update adds a boxed warning for hematologic malignancy risk, restricts use to CALD patients without a suitable HLA matched stem cell donor, and mandates enhanced long term monitoring. This change improves patient safety, aligns treatment with the latest risk data, and strengthens post marketing surveillance, though it may limit the eligible patient pool.

What Are Latest Mergers And Acquisitions In The Skysona Market?

In September 2023, Bluebird Bio, Inc., a US-based biotechnology company, revised its agreement with Lonza Group AG. With this collaboration, Lonza aims to enhance its manufacturing capabilities to support the production of Bluebird bio’s gene therapies, Zynteglo and Skysona, ensuring scalable, high-quality manufacturing processes to meet increasing demand and accelerate the delivery of these innovative treatments for rare diseases, including thalassemia and cerebral adrenoleukodystrophy (CALD). Lonza Group AG is a Switzerland-based contract manufacturing organization engaged in the manufacturing of skysona.

Regional Insights

North America was the largest region in the skysona market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

What Defines the Skysona Market?

The skysona market consists of sales of infusion bags, with the dose based on patient weight. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Skysona Market Report 2026?

The skysona market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the skysona industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.